Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

(2019) Zong Sheng Guo et al.   Journal for ImmunoTherapy of Cancer

An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers

(2019) Alessia Pin et al.   Diagnostics

Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance

(2019) Fan Sun et al.   Nature Communications

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

(2018) E E Vokes et al.   ANNALS OF ONCOLOGY

The Immune Revolution: A Case for Priming, Not Checkpoint

(2018) Robert H. Vonderheide   CANCER CELL

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers

(2018) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

Oncolytic viruses and immunity

(2018) Shyambabu Chaurasiya et al.   CURRENT OPINION IN IMMUNOLOGY

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

(2018) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones

(2018) Nikolas Tim Martin et al.   MOLECULAR THERAPY

Superagonist IL-15-armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade

(2018) Stacy J. Kowalsky et al.   MOLECULAR THERAPY

NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8+ T cells for tumor promotion

(2018) Liwen Li et al.   OncoImmunology

Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2

(2018) Zuqiang Liu et al.   Nature Communications

Tim-3 and its role in regulating anti-tumor immunity

(2017) Madhumita Das et al.   IMMUNOLOGICAL REVIEWS

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation

(2017) Jingjiao Zhou et al.   Cancer Immunology Research

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers

(2016) Stephanie Downs-Canner et al.   MOLECULAR THERAPY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer

(2015) Z. Qu et al.   CANCER RESEARCH

Oncovirus Kaposi Sarcoma Herpesvirus (KSHV) Represses Tumor Suppressor PDLIM2 to Persistently Activate Nuclear Factor κB (NF-κB) and STAT3 Transcription Factors for Tumorigenesis and Tumor Maintenance

(2015) Fan Sun et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity

(2015) Herbert J Zeh et al.   MOLECULAR THERAPY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function

(2015) F Sun et al.   ONCOGENE

Differential roles of STAT3 in the initiation and growth of lung cancer

(2014) J Zhou et al.   ONCOGENE

Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape

(2014) A. C. Anderson   Cancer Immunology Research

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

PDLIM2 restricts Th1 and Th17 differentiation and prevents autoimmune disease

(2013) Zhaoxia Qu et al.   Cell and Bioscience

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

The tumor suppressor gene WWOX links the canonical and noncanonical NF- B pathways in HTLV-I Tax-mediated tumorigenesis

(2010) J. Fu et al.   BLOOD

Epigenetic Repression of PDZ-LIM Domain-containing Protein 2

(2010) Zhaoxia Qu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8+ T Cells by Rapid Induction of Multiple Inhibitory Receptors

(2010) S. Takamura et al.   JOURNAL OF IMMUNOLOGY

PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation

(2009) P. Yan et al.   BLOOD

Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells

(2009) L. Golden-Mason et al.   JOURNAL OF VIROLOGY

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

(2008) R. Brad Jones et al.   JOURNAL OF EXPERIMENTAL MEDICINE